A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III, Efficacy and Safety Study of Intravaginal Prasterone (INTRAROSA) on Postmenopausal Vulvovaginal Atrophy (VVA)
Latest Information Update: 04 Nov 2022
At a glance
- Drugs Prasterone (Primary)
- Indications Atrophic vaginitis
- Focus Registrational; Therapeutic Use
- Sponsors Lee's Pharmaceutical
- 31 Oct 2022 Planned End Date changed from 31 Dec 2022 to 30 Mar 2023.
- 31 Oct 2022 Planned primary completion date changed from 30 Sep 2022 to 30 Jan 2023.
- 31 Oct 2022 Status changed from not yet recruiting to active, no longer recruiting.